BCG Vaccine Effective in Fighting COVID-19 |美日研究:卡介苗可助人體 對抗新冠病毒

The BCG vaccine protects against tuberculosis. Now researchers are trying to find out if the 100-year-old vaccine can help us combat COVID-19. Studies from Japan and the U.S. show promising results.


A latest study conducted by the U.S. and Japan has shown that the Bacillius Calmette-Guerin vaccine (BCG), which is effective in preventing tuberculosis, might be able to assist the human body in combating the novel coronavirus. Big data analysis of 68 countries showed that the confirmed cases of COVID-19 and the death rates are lower in which BCG vaccine is mandatory, such as France and Finland. Domestic experts also think the BCG vaccine is effective in enhancing the immune system to fight off different viruses and bacteria.

Your immune system reaction becomes better once you've gotten a BCG shot. The vaccine is responsive to all kinds of viruses and bacteria, including tuberculosis. This is because the vaccine can train our congenital immune response.

An expert on infectious disease in China pointed out the novel coronavirus could not be completely eliminated by this summer and predicted that the next peak of the pandemic would appear in November. Doctors in Taiwan said the coronavirus continues to mutate and evolve like influenza does. Both influenza and COVID-19 is likely to hit during fall and winter of this year. The doctor reminded people not to let their guards down.

COVID-19 would hit you once again as the weather turns colder and your guards are down. Number of confirmed cases would rise once again. The peak period would fall around after July and August, which bring us to fall and winter.

New foreign research done on the clinical testing drug, Remdesivir, has shown promising results in curing COVID-19. Seventy percent of the 53 confirmed patients who were hospitalized and had serious pneumonia complications have improved after taking the drug. The research included 9 severe cases of COVID-19 who have taken the drug in Taiwan. Hopefully, the clinical trials could expand and benefit more patients from Taiwan.



打一針就可以預防結核病的卡介苗！美國和日本最新研究發現，也可以協助人體、對抗引發武漢肺炎的新型冠狀病毒，而且透過大數據模型計算發現，強制接種卡介苗的68個國家，包括法國、芬蘭等，武漢肺炎的確診數及死亡率都明顯較低，而國內專家也認為，卡介苗有助於提升免疫系統，可以對抗不同病毒和細菌。

台灣感染症醫學會理事長 黃立民表示：「你打過卡介苗以後，你的免疫反應整個會變好。不管對什麼，不管對結核菌，或對別的病毒，整個都會變好。那這個主要，是因為它可以訓練我們的先天性免疫反應。」

此外，有中國感染症專家指出，今年夏天不可能完全清除新冠肺炎病毒，並且預測下一波疫情、應該在11月分到來；對此國內醫師表示，新型冠狀病毒還在繼續演化突變，跟流感模式差不多，尤其今年秋冬，很可能是流感跟武漢肺炎疫情、同時爆發，民眾防疫更不可鬆懈。

台灣感染症醫學會理事長 黃立民表示：「等到天氣涼一點，你的防疫措施，鬆懈一點的時候，它又開始，病人又變多。那個時候，大概是七、八月以後的事情了，那反正秋天跟冬天呢，基本上，被認為是一個高峰期啦！」

至於臨床試驗藥品「瑞德西韋」，國外最新研究報告指出，53名住院、並且有嚴重肺炎併發症患者，使用藥物後，有近七成患者、病情獲得改善，而這分研究也包含我國使用「瑞德西韋」的9名重症個案，未來臨床試驗再擴大，台灣患者也可望受惠。